Index Ventures has announced the launch of a new €150 million fund to support early-stage, research intensive companies in the life science sector. Significantly, the fund is being financially supported by GlaxoSmithKline Plc and the venture capital affiliate of Johnson & Johnson Inc. Representatives from both multinationals will sit on the fund’s scientific advisory board.
